A newer medication, tenecteplase, is also a clot-busting medication and is a bioengineered variant of alteplase, and there are ongoing studies to determine its safety, efficacy and treatment parameters for ischaemic stroke. Previous studies of tenecteplase to treat acute ischaemic stroke pat...
STROKE treatmentTHROMBOLYTIC therapyNEUROPROTECTIVE agentsNEUROPLASTICITYNEURONSNarrow therapeutic window limits treatments with thrombolysis and neuroprotection for most stroke patients. Widening therapeutic window remains a critical challenge. Understanding the key mechanisms underlying the pathophysiological events in ...
While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy. 展开 关键词: Tissue plasminogen activator Hemorrhage Vasculature Blood-brain barrier ...
Endovascular treatment for acute ischemic stroke has the potential to substantially improve the outcome for select individual stroke patients. However, the impact of this treatment on a population scale is unknown. We reviewed the epidemiology of acute stroke presentation times to estimate the proportion...
Worsening in ischemic stroke patients: is it time for a new strategy? Stroke. 2002;33:1443–5. Article CAS PubMed Google Scholar Lin YH, Dong J, Tang Y, Ni HY, Zhang Y, Su P, et al. Opening a new time window for treatment of stroke by targeting HDAC2. J Neurosci. 2017;37:...
Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window. Stroke. 2009;40(7):2433-243719498197PubMedGoogle ScholarCrossref 13. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number ...
Patients and doctors long have relied on a simple rule of thumb for seeking care after an ischemic stroke: "Time is brain."
Early treatment of ischemic stroke with thrombolytics is associated with improved outcomes, but few stroke patients receive thrombolytic treatment in part due to the 3-hour time window. Advances in neuroimaging may help to aid in the selection of patients who may still benefit from thrombolytic trea...
Reperfusion therapy for acute stroke has evolved from the initial use of intravenous tissue plasminogen activator (tPA) within 3 hours of symptom onset to more recent guideline-recommended use up to 4.5 hours. In addition, endovascular therapy is increasingly utilized for stroke treatment and is typ...
Time is of the essence when it comes to stroke treatment. But a new image guided technique could help shift the criterion from one that is determined by how long after the start of symptoms a patient receives medical care, suggests a small US study published online in theJournal of NeuroInt...